{
    "2018-03-28": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Intel",
                        "Procter & Gamble",
                        "Research Reports"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "consumer goods"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "How Did Novartis Perform in 4Q17 and Full-Year 2017?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "4Q17",
                        "Full-Year 2017"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "3 Dow Stocks to Buy Amid Tech Selloff",
                "features": {
                    "keywords": [
                        "Dow Stocks",
                        "Tech Selloff"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "FDA working on a \"dozen\" policies to boost copycat biotech drugs",
                "features": {
                    "keywords": [
                        "FDA",
                        "policies",
                        "biotech drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV)",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "SAFE Dividend",
                        "Yield"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma",
                "features": {
                    "keywords": [
                        "Drug Prices",
                        "Outcome-Based Pricing",
                        "Biopharma"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Big Pharma's billion-dollar scramble to invest in start-ups to fuel innovation",
                "features": {
                    "keywords": [
                        "Big Pharma",
                        "start-ups",
                        "innovation"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}